X

Trial Profile

Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of VNRX-9945 in Healthy Adult Volunteers

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 23 Jun 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VNRX-9945 (Primary)
Indications Hepatitis B
Focus Adverse reactions; First in man
Sponsors VenatoRx Pharmaceuticals

Most Recent Events

14 Jun 2022 Status changed from active, no longer recruiting to discontinued.
10 Nov 2021 Status changed from recruiting to active, no longer recruiting.
28 Jun 2021 According to a VenatoRx Pharmaceuticals media release, first patient has been dosed in this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com